Seladelpar

ID: seladelpar

Aliases: Livdelzi, seladelpar lysine dihydrate

Type: compound

Route/form: oral or route depends on studied product

Status: approved

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human

Source types: human_rct, label

Linked sources: 3

Broad outcomes: Fat loss / metabolic health, Gut / immune / inflammation

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• PPAR-delta agonist

Optimization domains

• PBC
• liver
• metabolic

Research basis

• Label-level source identifies PPAR-delta agonism and approved PBC context.
• Relevant to PPAR-delta enthusiasm because real clinical indication is cholestatic liver disease, not generic fat loss.

Limits, risks, and missing evidence

• Approved indication should not be extrapolated to body composition without evidence.
• Liver-disease drug monitoring and indication-specific risk/benefit apply.

Risk flags

• prescription
• liver
• medical supervision

Linked papers, labels, and reviews

1. FDA label: seladelpar lysine
   label / fda_seladelpar_label_2026
   Official label identifies seladelpar as a PPAR-delta agonist.
2. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
   human_rct / pubmed_seladelpar_response_2024
   RESPONSE phase 3 RCT in PBC; direct clinical efficacy source for seladelpar's approved disease context.
3. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE
   human_rct / pubmed_seladelpar_enhance_2023
   ENHANCE phase 3 randomized placebo-controlled PBC study; adds direct human clinical context beyond the label.